Vaccine Pharmacology
Vaccine types, adjuvant mechanisms, immune response kinetics, mRNA platform technology, and pharmacological principles underlying vaccination.
Principles of Vaccination
Vaccines exploit immunological memory to generate protective immunity without causing disease. They present antigens to the adaptive immune system, inducing B-cell (antibody) and T-cell (cellular) responses. Upon subsequent pathogen encounter, memory cells mount rapid, high-affinity responses that prevent or attenuate disease.
The pharmacology of vaccines encompasses antigen design, adjuvant selection, delivery route, dosing schedule, and storage requirements.
Vaccine Platforms
Live attenuated vaccines (MMR, varicella, yellow fever) use weakened pathogens that replicate limitedly, generating robust humoral and cellular immunity. Contraindicated in immunocompromised patients.
Inactivated vaccines (hepatitis A, influenza) use killed whole pathogens. They produce primarily antibody responses and typically require multiple doses and boosters.
Subunit/protein vaccines (hepatitis B, HPV, shingles-Shingrix) contain purified antigens. They are safe in immunocompromised patients but require adjuvants for adequate immunogenicity.
mRNA vaccines (COVID-19 Pfizer-BioNTech, Moderna) deliver lipid nanoparticle-encapsulated mRNA encoding the target antigen. Host cells translate the mRNA into protein, which is processed and presented via MHC class I and II, eliciting both antibody and cytotoxic T-cell responses. The mRNA is degraded within days.
Viral vector vaccines (COVID-19 J&J/AstraZeneca, Ebola) use replication-deficient adenoviruses to deliver antigen-encoding DNA. Pre-existing immunity to the vector can reduce effectiveness.
Adjuvants
Adjuvants enhance vaccine immunogenicity by activating innate immunity at the injection site. Key adjuvants include:
- Aluminum salts (alum): Most widely used. Create antigen depot and activate NLRP3 inflammasome
- AS01 (Shingrix): MPL + QS-21 in liposomes. Potent T-cell response induction
- AS04 (Cervarix): MPL + alum. TLR4 agonist activity
- MF59 (some influenza): Squalene oil-in-water emulsion. Enhances antigen uptake by APCs
Immune Response Kinetics
Primary vaccination induces a lag phase (5-7 days), followed by IgM production, then IgG class switching. Peak antibody titers occur at 2-4 weeks. Booster doses drive affinity maturation in germinal centers, producing higher-affinity IgG and expanding memory B-cell populations. This is why multi-dose schedules with appropriate intervals (typically 4-8 weeks) are pharmacologically essential.
Special Populations
Immunocompromised patients may have diminished vaccine responses. Live vaccines are generally contraindicated. Higher doses or additional boosters may be needed (e.g., double-dose hepatitis B in dialysis patients). Timing vaccines relative to immunosuppressive therapy is critical -- ideally 2-4 weeks before initiating B-cell depleting agents.
Key Takeaways
- mRNA vaccines induce both humoral and cellular immunity via endogenous antigen expression
- Adjuvants activate innate immunity to amplify adaptive responses
- Booster doses drive affinity maturation and long-lived memory cell expansion
- Live vaccines are contraindicated in immunocompromised patients